Pasithea Therapeutics Files S-1 Registration Statement
Ticker: KTTAW · Form: S-1 · Filed: May 1, 2025 · CIK: 1841330
Sentiment: neutral
Topics: s-1, registration-statement, sec-filing, pharmaceutical
TL;DR
Pasithea Therapeutics just filed an S-1, looks like they're gearing up for a public offering.
AI Summary
Pasithea Therapeutics Corp. filed an S-1 registration statement with the SEC on May 1, 2025, to register securities under the Securities Act of 1933. The company, incorporated in Delaware with its principal executive offices in Miami Beach, Florida, is in the pharmaceutical preparations industry. The filing includes details about the company's business, financial condition, and the securities being offered, though specific dollar amounts for the offering are not detailed in this excerpt.
Why It Matters
This S-1 filing indicates Pasithea Therapeutics is preparing to offer new securities to the public, which could impact its capital structure and future growth prospects.
Risk Assessment
Risk Level: medium — S-1 filings are typically associated with initial public offerings or significant secondary offerings, which inherently carry market and execution risks.
Key Numbers
- 333-286889 — SEC File Number (Identifies the specific registration statement with the SEC.)
- 0001841330 — Central Index Key (Unique identifier for the company in the SEC's EDGAR system.)
- 1231 — Fiscal Year End (Indicates the end of the company's annual accounting period.)
Key Players & Entities
- Pasithea Therapeutics Corp. (company) — Registrant
- Tiago Reis Marques (person) — Chief Executive Officer
- James O’Grady, Esq. (person) — Legal Counsel
- Lowenstein Sandler LLP (company) — Legal Counsel
- Miami Beach, Florida (location) — Principal Executive Offices
- Delaware (location) — State of Incorporation
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public, as per the Securities Act of 1933.
When was this S-1 filing submitted?
The S-1 filing was submitted to the SEC on May 1, 2025.
Where are Pasithea Therapeutics Corp.'s principal executive offices located?
The company's principal executive offices are located at 1111 Lincoln Road, Suite 500, Miami Beach, Florida 33139.
Who is the Chief Executive Officer of Pasithea Therapeutics Corp.?
Tiago Reis Marques is the Chief Executive Officer of Pasithea Therapeutics Corp.
Which law firm is representing Pasithea Therapeutics Corp. in this filing?
Lowenstein Sandler LLP, with James O’Grady, Esq. as a contact, is representing Pasithea Therapeutics Corp. for this filing.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on May 1, 2025 by Tiago Reis Marques regarding Pasithea Therapeutics Corp. (KTTAW).